Earnings ·
Reports Q3 net loss of $1.55 per share and closes $575M equity and debt offering
VKTXViking Therapeutics, Inc.
Viking Therapeutics reported a third-quarter 2026 net loss of $183.2 million, or $1.55 per share, compared to a $90.8 million loss in the prior-year period. The widening deficit was driven by research and development expenses rising to $166.8 million from $90.0 million, alongside general and administrative costs increasing to $20.3 million from $8.6 million. The company also announced the successful closing of concurrent upsized public offerings of common stock and convertible senior notes in September, generating approximately $575 million in gross proceeds. This financing brought quarter-end cash, cash equivalents, and short-term investments to a strong balance of $960 million. Clinically, Viking initiated the SUNRISE Phase 3 trials for its oral VK2735 formulation and reported positive maintenance dosing results from Part 1 of its range-finding study. The company operates as a clinical-stage biopharmaceutical firm focused on developing novel therapies for metabolic and endocrine disorders.